Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06299826 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT06299826 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 375 participants.
The verdict
NCT06299826, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).
Interventions
- DRUG Placebo
- DRUG AZD5462
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2026-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06299826
The ClinicalTrials.gov registry entry for NCT06299826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06299826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06299826 about?
NCT06299826 is a clinical study titled "A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure". The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).
What is the current status of trial NCT06299826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2024-06-04. Estimated completion is 2026-02-10.
What interventions are being tested in trial NCT06299826?
The interventions under investigation include: Placebo (DRUG), AZD5462 (DRUG).
Who is sponsoring clinical trial NCT06299826?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.